Emory vs. Vanderbilt FACE-OFF: Novel Therapies Demonstrate Efficacy in Relapsed/Refractory Hematologic Malignancies

home / face-off / multiple-myeloma-face-off-emory-university-vs-vanderbilt-university

A panel of experts analyzed and discussed phase 2&3 trial findings on efficacy and safety of emerging targeted therapies such as ADCs, bispecific, and CAR-T cells for relapsed/ refractory blood cancers.

Cancer Network Face-Off: Introduction of Relapsed/Refractory Multiple Myeloma

EP. 1: Cancer Network Face-Off: Introduction of Relapsed/Refractory Multiple Myeloma

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH
January 15th 2024

A summary of key discussion points and an overview of the evidence presented to inform the dialogue.

Outcomes After Biochemical or Clinical Progression in Patients With Multiple Myeloma

EP. 2: Outcomes After Biochemical or Clinical Progression in Patients With Multiple Myeloma

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH
January 22nd 2024

Examine outcomes such as overall survival, progression-free survival, and response rates in multiple myeloma patients who have experienced biochemical or clinical progression after prior lines of therapy.

Real-World Effectiveness of Ixazomib Combined With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

EP. 3: Real-World Effectiveness of Ixazomib Combined With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH
January 22nd 2024

Present real-world data on the efficacy and safety of the ixazomib-lenalidomide-dexamethasone combination in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

EP. 4: Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH
January 29th 2024

Compare outcomes between ide-cel chimeric antigen receptor T-cell (CAR-T) therapy and standard treatment regimens such as pomalidomide and daratumumab combinations in patients with heavily pretreated relapsed and refractory multiple myeloma.

First Results From the RedirecTT-1 Study With Teclistamab + Talquestamab Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma

EP. 5: First Results From the RedirecTT-1 Study With Teclistamab + Talquestamab Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH
January 29th 2024

Present initial results from the Phase 1 RedirecTT-1 trial exploring the combination of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results

EP. 6: Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH
February 5th 2024

Examine the efficacy and safety of the BCMA-targeting bispecific antibody elranatamab as monotherapy and in combinations from the Phase 2 MagnetisMM-3 trial in patients with relapsed or refractory multiple myeloma.